and mortality in patients with chemotherapy-induced neutropenia. Chlorhexidine containing catheter securement dressings may prevent CRBSI.
introduction
The administration of intensive chemotherapy for a hematological malignancy frequently requires the insertion of a central venous catheter (CVC). Particularly during long-term use of nontunneled CVC, catheter-related bloodstream infections (CRBSI) may occur [1] , ranging from 2.5 to 7.5 infections per 1000 catheter days [2] [3] [4] . In neutropenic patients, mortality due to CRBSI has been reported to be as high as 36% [5] .
Previous studies have highlighted the role of skin colonization as a predisposition for catheter colonization and subsequent CRBSI [3] . Consequently, effective reduction in skin colonization may be an important preventive factor. A few randomized trials have shown reduction in CRBSI by the use of dressings with chlorhexidine gluconate (CHG)-impregnated sponges [6] [7] [8] or a CHG-containing gel pad [9] . The transparent gel pad has the advantage of allowing visual evaluation of the CVC insertion site without dressing removal. The two largest studies were conducted in intensive care unit (ICU) patients [7, 9] ; only one study evaluated the clinical efficacy of CHG CVC dressings in patients undergoing chemotherapy [6] . All three studies showed reduced CVC-related infection rates for CHG dressings. The application of CHG dressings is recommended by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) [10] , but not by the American Society of Clinical Oncology (ASCO) [11] . The Centers for Disease Control considers chlorhexidine dressings other than those with impregnated sponges an unresolved issue [1] .
Due to the limited body of evidence and the conflicting recommendations, a multicenter randomized, controlled trial investigating CVC dressings with CHG-containing gel pads in the setting of high-risk neutropenic patients was conducted.
methods study design
We conducted an open-label, randomized, multicenter trial in 10 German hematological departments. We compared two securement dressings with regard to their safety and efficacy in preventing CRBSI. The study product 3M™ Tegaderm™ CHG I.V. is a transparent CVC dressing with a chlorhexidine-containing gel pad. The comparator, 3M™ Tegaderm™ I.V. Advanced is a transparent CVC dressing without an antimicrobial gel pad. The study was designed and planned according to the Declaration of Helsinki in the version of October 2008 (59th WMA General Assembly, Seoul). Ethical approval was obtained from all competent ethics committees and registration completed at Clinicaltrials.gov (NCT01544686).
study patients
Patients undergoing chemotherapy with an expected duration of chemotherapy-induced neutropenia of ≥5 days and an expected CVC use of ≥10 days were eligible for inclusion. Patients could be enrolled only once. Exclusion criteria included the use of tunneled CVC, shaldon catheters, femoral insertion and suspected or confirmed bacterial infection at randomization.
trial conduct
After informed consent, patients received a non-tunneled CVC in the subclavian or internal jugular vein. The type of CVC used depended on local standards, insertion followed a strict antiseptic regimen in accordance with respective guidelines [1, 12] .
Dressings were applied within 2 h of CVC placement and changed every 3 ± 1 days.
In the case of neutropenic fever, central and peripheral blood cultures were drawn. If there was a suspicion of CRBSI, the CVC was removed and the tip sent in for microbiological culture. Antimicrobial prophylaxis or treatment depended on local standards, antimicrobial stewardship programs were not conducted during the study period. End of treatment (EOT) was determined as CVC change or removal for any reason, definite CRBSI with or without CVC removal, maximum treatment duration of 42 days as per protocol, intolerance to the study product or death. Adverse events (AEs) and severe adverse events (SAEs) were assessed until follow-up on day 14 after EOT. Independent data monitors reviewed documentation.
variables and definitions
Documented variables included demographics, underlying disease, chemotherapeutic regimen, CVC characteristics, dressing changes, neutropenia, occurrence of neutropenic fever and antibiotic or antifungal administration during study treatment. In patients with CRBSI, results from blood and CVC tip cultures, presence of clinical signs according to the applied definitions and presence of an alternative focus were recorded.
CRBSI were defined according to the AGIHO-DGHO guidelines [12] . Definite CRBSI required either a differential time to positivity (DTTP) over 2 h in a pair of peripheral and central blood cultures or the detection of the same pathogen with the same susceptibility pattern in a blood culture and at the catheter tip. For probable CRBSI, one of the following three scenarios needed to be fulfilled: the presence of local infection at the insertion site with at least two signs of inflammation coupled with a positive blood culture; remission of previously refractory fever within 48 h after catheter removal plus a positive blood culture; or a positive catheter tip culture.
Definition of severe sepsis as modified from the guidelines by American College of Chest Physicians and the Society of Critical Care Medicine [13] required the following two criteria: (i) systemic inflammatory response (SIRS) and (ii) at least one organ dysfunction.
Since this study investigated an already approved medical product within its licensed indication, assessment of AE and SAE was not mandatory by applicable local law. Thus, AEs were restricted to cutaneous and soft tissue abnormalities, AE in relation with systemic allergic reactions and AE in relation with coagulation disorders not related to chemotherapy-associated thrombocytopenia.
end points
The primary end point was incidence of definite CRBSI within 14 days (dCRBSI14) of CVC placement. Secondary end points were overall definite CRBSI (dCRBSI), definite and probable CRBSI within 14 days of CVC placement (dpCRBSI14), overall definite and probable CRBSI (dpCRBSI), dCRBSI14-related severe sepsis, dCRBSI14-related mortality, dpCRBSIrelated severe sepsis, dpCRBSI-related mortality, overall mortality, time to removal of CVC or EOT, time to dpCRBSI, time to first neutropenic fever and the frequency and reasons of unscheduled dressing changes (UDC).
sample size and statistical analysis
A group-sequential design using O'Brien and Fleming bounds at information fractions 0.5 and 1 was chosen to allow for early termination of the trial due to futility or success. We assumed a reduction in dCRBSI14 from 12% in the control group to 7.2% in the CHG group. Based on a two-sided type I error α = 0.05, 1190 assessable patients were calculated to reach a power of 1 − β = 0.8 (χ 2 test without continuity correction). Compensating for a percentage of ∼5% non-assessable patients, we planned to include 1260 patients. Analysis of the intention-to-treat (ITT) population included all randomized and evaluable subjects: all who received a CVC and did not withdraw consent directly after randomization. The primary end point dCRBSI14 was evaluated by a Mantel-Haenszel test stratified by study center, testing if the combined odds ratio equals 1. Characteristics of patients, catheters and dressings were described as count (%) or median (inter-quartile range) for qualitative and quantitative variables and compared between treatment groups using the χ 2 test, Wilcoxon rank-sum test or log-rank test as appropriate.
Corresponding confidence intervals (CI) were calculated if possible. Subgroup analyses referred to CVC insertion site ( jugular or subclavian vein) and CVC type (coated versus non-coated). P values smaller 5% were considered 'statistically significant'. SPSS Statistics software (Version 22, IBM Corp., Armonk, NY) was used. primary and secondary end points
For dCRBSI14, the rates were not significantly different between groups (CHG: 2.6% versus control: 3.9%; odds ratio: 0.676; 95% CI 0.270-1.693). Both, dpCRBSI14 (CHG: 6.5% versus control: 11.1%; P = 0.047) and dpCRBSI (CHG: 10.4% versus control: 17.3%; P = 0.014), were significantly less frequent in the study Table S1 , available at Annals of Oncology online), a differentiation of the CRBSI criteria applied (supplementary Table S2 , available at Annals of Oncology online) and incidences per center (supplementary Table S3 , available at Annals of Oncology online) are shown in the supplementary material, available at Annals of Oncology online.
Regarding frequencies of CRBSI-related severe sepsis and mortality, overall mortality, time to removal of CVC, time to dpCRBSI and time to first neutropenic fever, there were no significant differences (Table 2 ). There were significantly fewer UDC in the study than in the control group reflected in the mean number of UDCs per patient (CHG: 0.9 versus control: 1.2) and the difference in total UDC (CHG: 269 versus control: 362; P = 0.030). The most frequent reason for a UDC was intensive bleeding documented in 73 (23.8%) CHG and 83 (27.1%) control patients (P = 0.355), followed by insufficient cutaneous adhesion in 43 (14%) CHG and 72 (23.5%) control patients (P = 0.003).
safety and tolerability
In total, 56 AEs in 51 patients (16.6%) were observed in the CHG and 57 AEs in 52 patients (17.0%) in the control group (P = 0.914). AEs concerning cutaneous and soft tissue abnormalities were observed in 38 patients (12.4%) in the CHG and 36 (11.8%) in the control group (P = 0.901). In 22 cases (7.2%) in the CHG and 24 cases (7.8%) in the control group, this intolerance lead to study discontinuation and definite change to different dressing (P = 0.762). In 33 study (10.7%) and 32 control patients (10.5%), an AE was classified as certainly or probably related to the respective dressing. All of these related AEs were cutaneous and soft tissue abnormalities.
Regarding SAEs, 42 events were documented in 39 CHG (12.7%) and 36 events in 32 control patients (11.8%). The most frequently reported SAEs were organ failures related to severe sepsis. None of the SAEs were assessed as certainly or probably related to the study treatment (Table 3) .
pathogens causing CRBSI
The distribution of causative pathogens in dpCRBSI did not differ significantly between groups with coagulase-negative staphylococci being the most frequently isolated pathogens (supplementary Table S4 , available at Annals of Oncology online).
CVC insertion site and type
The distribution of CVC insertion site and CVC type was similar between groups (see supplementary Table S5 , available at Annals of Oncology online for frequencies per center). To further assess a possible influence of these variables, we examined the CRBSI rates according to CVC insertion site and CVC type irrespective of randomization (supplementary Table S6 , available at Annals of Oncology online). Rates were significantly higher in patients with a subclavian vein when compared with a jugular internal vein CVC both for dCRBSI14 (4.8% versus 1.2%; P = 0.019) and dCRBSI (8.1% versus 3.1%; P = 0.010). Comparing coated versus uncoated CVC, patients with coated CVC had higher rates of dCRBSI14 (4.2% versus 1.1%; P = 0.048), dCRBSI (7.9% versus 1.6%; P = 0.001) and dpCRBSI (16.4% versus 8.1%; P = 0.007).
discussion
To our knowledge, this is the first randomized trial evaluating a transparent CVC dressing with a chlorhexidine gel pad in neutropenic patients. A trend toward reduction was seen for the primary end point of definite CRBSI within 14 days of CVC placement, but due to a lower than expected event rate, the study was underpowered with respect to its primary end point. Application of the study dressing in comparison to a transparent non-CHG dressing significantly reduced the incidence of definite and probable CRBSI overall from 17.3% to 10.4% (P = 0.014) and within 14 days of CVC placement from 11.1% to 6.5% (P = 0.047), respectively. These results are consistent with those of previous studies investigating chlorhexidine-containing CVC dressings in different settings [6] [7] [8] [9] and thus complement the evidence in favor of application of transparent CHG dressings for non-tunneled CVC in the setting of neutropenia. Given that the identified etiological agents were mostly skin colonizers, the more marked preventive efficacy in overall CRBSI rates when compared with rates within 14 days of CVC placement suggests that the effect of the dressing in reducing skin colonization is not limited to the first 14 days of its use. The risk of extraluminal contamination of the CVC, most likely not affected by our study product, is an independent, additional risk factor for CRBSI. We observed no difference in the rates of CRBSI-related severe sepsis or mortality between the two groups. However, the infrequency of these clinical outcomes limited the ability of a study of this size in detecting a possible difference. Furthermore, both, severe sepsis and overall mortality, are-obviously-not merely influenced by the applied CVC dressing in these highrisk patients.
It is noteworthy that intolerance to the study product as a reason for EOT as well as adverse events concerning skin and soft tissue abnormalities did not occur significantly more frequent in the study group. Skin defects were observed in only few cases in both groups. This opposes findings of previous studies reporting increased rates of contact dermatitis during the application of CHG containing dressings [9, 14] . We hypothesize that the comparatively short interval between dressing changes (3 ± 1 days) might have prevented skin reactions triggered by moisture accumulating between skin and dressing.
Unexpectedly, the incidence of CRBSI was lower in patients with internal jugular when compared with subclavian insertion site and in those with uncoated CVCs when compared with coated, irrespective of dressing randomization. Regarding CVC insertion site, results are contradictory to previous studies reporting lower CRBSI rates for subclavian insertion site [15, 16] . However, a Cochrane review found similar infection rates for subclavian and internal jugular insertion sites [17] . Regarding CVC type, our results contradict various studies and literature reviews favoring coated CVCs with respect to CRBSI [18] [19] [20] [21] . Antimicrobial or antiseptic coated CVCs are recommended in German [10] and American [11] guidelines. However, the advantage of coated CVCs might be more pronounced in ICU settings [22] , in short-term catheterization under 7 days [23] and was not confirmed in a meta-analysis evaluating CVCs for parenteral nutrition and chemotherapy [24] . Of note, the present study was not designed and the study population not stratified for analyzing the impact of CVC insertion site and coating on CRBSI. The choice of CVC type and insertion site depended on the standard of care of the respective study center. Our study has some limitations. First, the study was terminated after the interim analysis due to the low rate of primary end point events. Therefore, the study lacks adequate power, particularly regarding the conservative O'Brien-Fleming bound 0.002583 (one-sided). The incidence of the primary end point dCRBSI14 was lower than anticipated from previous observations [6] -possibly being a result of improved antiseptic routine. Secondly, due to a lack of a control product including a gel pad without antimicrobial activity, blinding was not feasible. Nevertheless, the microbiological department was blinded as blood cultures and CVC tips were analyzed within routine diagnostics. The substantial sample size within this special setting of neutropenic patients, the multicenter design and the thorough assessment of adverse events are key strengths of the presented study.
In summary, the study was not able to demonstrate a reduction in the primary end point of definite CRBSI within 14 days of CVC placement by the application of transparent CVC dressings with a chlorhexidine-containing gel pad in patients undergoing intensive chemotherapy. The presented results show that the dressings were well tolerated and significantly reduced definite and probable CRBSI. Whether the observed risk reduction for definite and probable CRBSI justifies the application of CHG dressings in the routine care of long-term neutropenic patients also depends on further factors such as local CRBSI rates and related costs.
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